Placebo RVX000222

DRUG2 trials

Sponsors

Resverlogix Corp

Conditions

Coronary Artery DiseaseDyslipidemia

Phase 2

ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

CompletedNCT01067820

Resverlogix CorpCoronary Artery Disease

Start: 2011-09-30End: 2013-06-30Updated: 2013-06-04

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

CompletedNCT01423188

Resverlogix CorpCoronary Artery Disease, Dyslipidemia

Start: 2011-08-31End: 2012-08-31Updated: 2012-09-20

Related Papers

The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

2019-02-0128 citations

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.

2016-02-0179 citations

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

2012-04-0168 citations